ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Oncology · Breast Cancer Res Treat · 2026-11-14

Meta-analysis of 7 randomised contrasts (2,627 participants) in non-metastatic TNBC: adding carboplatin to comparable chemotherapy improved disease control (HR 0.779) and pCR (OR 2.04), but overall survival benefit was not established (HR 0.810, p=0.107).

Meta-analysisn = 2,627
Wu et al. Survival benefit of adding carboplatin to standard anthracycline-taxane chemotherapy in triple-negative breast cancer: an updated systematic review and meta-analysis
Ear, nose and throat · Head Neck · 2026-10-05

Meta-analysis of 8 randomised and observational studies (1044 patients) in head and neck SCC: no significant difference between cisplatin- and carboplatin-based regimens in OS, PFS, LRRFS, DMFS or grade ≥3 toxicity; 5-year LRRFS modestly favoured cisplatin (2 studies).

Meta-analysisn = 1,044
Rahim et al. Efficacy and Safety of Cisplatin Versus Carboplatin for Patients With Squamous Cell Carcinoma of Head and Neck: A Systematic Review and Meta-Analysis
Oncology · Lancet Oncol · 2026-07-01

In 174 women with stage III HER2-negative HRD breast cancer, intensified alkylating chemotherapy with stem cell rescue gave no 4-year overall survival advantage over chemotherapy then olaparib (77.0% vs 76.4%; HR 1.11), with more serious adverse events (47% vs 26%).

RCTn = 174
Seefat et al. Targeting homologous recombination deficiency with intensified chemotherapy versus standard chemotherapy followed by olaparib in stage III breast cancer (SUBITO): an open-label, randomised, controlled, phase 3 trial
Oncology · Ann Oncol · 2026-05-30

In 868 patients with stage II–III triple-negative breast cancer, adding carboplatin to anthracycline then taxane (neo)adjuvant chemotherapy improved event-free survival (5-year 82.3% vs 75.1%; HR 0.67) but raised grade ≥3 adverse events (74.7% vs 56.7%).

RCTn = 868
Kim et al. A randomized phase III trial of anthracyclines followed by taxane versus taxane plus carboplatin as (neo)adjuvant therapy in patients with triple-negative breast cancer: KCSG BR 15-1 PEARLY trial
Oncology · Gynecol Oncol · 2026-05-26

Secondary analysis of GOG-0249 (315 of 601 patients with high-intermediate/high-risk early endometrial cancer): 5-year RFS was 58.7% with p53abn (HR 4.0), 74.4% with dMMR and 83.4% with p53wt; molecular group did not predict benefit of VCB/chemotherapy vs pelvic RT.

Secondary analysisn = 315
Kuroki et al. Molecular classification and association with survival outcomes in high-intermediate and high-risk early-stage endometrial cancers: Ancillary analysis of GOG-0249
Oncology · ESMO Open · 2026-03-19

In a phase 2 trial of 150 patients with untreated metastatic triple-negative breast cancer, gemcitabine plus cisplatin did not significantly improve median PFS vs gemcitabine plus carboplatin (7.8 vs 7.0 months; HR 0.86, P=0.43); median OS was 20.3 vs 19.3 months.

RCTn = 150
Gong et al. A phase II randomized trial of gemcitabine plus cisplatin (GP) versus gemcitabine plus carboplatin (GC) as the first-line treatment of patients with metastatic triple-negative breast cancer
Oncology · J Clin Oncol · 2026-01-23

Phase III trial in 766 women with stage II-III HER2-positive breast cancer: neoadjuvant taxane, trastuzumab and pertuzumab without carboplatin was non-inferior to with carboplatin for pCR (64.1% vs 65.9%), with fewer grade 3-4 AEs (20.7% vs 34.6%).

RCTn = 774
Gao et al. Neoadjuvant Taxane Plus Trastuzumab and Pertuzumab With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: The Randomized Noninferiority Phase III neoCARHP Trial
Oncology · BMJ · 2025-12-23

In 808 women with high risk early triple negative breast cancer, adding carboplatin to adjuvant anthracycline/taxane chemotherapy gave estimated 3-year disease-free survival of 92.3% vs 85.8% (HR 0.64); benefit was early. Grade 3-4 adverse events: 66.7% vs 55.0%.

RCTn = 808
Liu et al. Effect of adjuvant carboplatin intensified chemotherapy versus standard chemotherapy on survival in women with high risk, early stage, triple negative breast cancer (CITRINE): randomised, open label phase 3 trial

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.